Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Hans M.G. Princen"'
Autor:
Elsbet J. Pieterman, Marianne G. Pouwer, Lori L. Jennings, Alain J. van Gool, Jan H.N. Lindeman, Maarten D. Sollewijn Gelpke, Danielle van Keulen, Hans M.G. Princen, Vilmundur Gudnason, Valur Emilsson, Gerard Pasterkamp, Kim Holmstrøm, Ljubica Perisic Matic, Boye Schnack Nielsen, Dennie Tempel, Ulf Hedin
Publikováno v:
PLoS ONE, 14(8). Public Library of Science
Plos One, 8, 14, e0221477
PLoS ONE
PLoS ONE, 14(8). PUBLIC LIBRARY SCIENCE
PLoS ONE, Vol 14, Iss 8, p e0221477 (2019)
Plos One, 8, 14, e0221477
PLoS ONE
PLoS ONE, 14(8). PUBLIC LIBRARY SCIENCE
PLoS ONE, Vol 14, Iss 8, p e0221477 (2019)
ObjectivePrevious studies indicate a role for Oncostatin M (OSM) in atherosclerosis and other chronic inflammatory diseases for which inhibitory antibodies are in development. However, to date no intervention studies with OSM have been performed, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9390ed769904473deef47d2afd5dee3
https://dspace.library.uu.nl/handle/1874/390802
https://dspace.library.uu.nl/handle/1874/390802
Autor:
Christian Werner, Susanne Schuster, Sandra Rubil, Matthias Endres, Karsten Winter, Ulrich Laufs, J.-N Boeckel, Hans M.G. Princen
Publikováno v:
Scientific reports 9(1), 11079 (2019). doi:10.1038/s41598-019-47242-0
Scientific Reports, 1, 9
Scientific Reports, Vol 9, Iss 1, Pp 1-8 (2019)
Scientific Reports
Scientific Reports, 1, 9
Scientific Reports, Vol 9, Iss 1, Pp 1-8 (2019)
Scientific Reports
LDL-cholesterol (LDL-C) is a causal pathogenic factor in atherosclerosis. Monoclonal anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) neutralizing antibodies are novel potent LDL-lowering drugs which reduce cardiovascular events. To charact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acb54ae668afdb61322526b07e37960e
Autor:
Hans M.G. Princen, R. Kleemann, A.E. Kozijn, Susan Kühnast, Simon C. Mastbergen, F.P.J.G. Lafeber, Harrie Weinans, Reinout Stoop, Lobke Gierman, E.J. Pieterman, R.A. van der Heijden, F. van der Ham, Anne-Marie Zuurmond, A.M. van den Hoek, Martine C. Morrison, A. Van Koppen, I. Bobeldijk, P.M. Stavro, Petra Mulder
Publikováno v:
Osteoarthritis and Cartilage, 26(1), 95. W.B. Saunders Ltd
Osteoarthritis and cartilage, 26(1), 95-107. ELSEVIER SCI LTD
Osteoarthritis and Cartilage, 1, 25, 95-107
Osteoarthritis and cartilage, 26(1), 95-107. ELSEVIER SCI LTD
Osteoarthritis and Cartilage, 1, 25, 95-107
Objective: Human cohort studies have demonstrated a role for systemic metabolic dysfunction in osteoarthritis (OA) pathogenesis in obese patients. To explore the mechanisms underlying this metabolic phenotype of OA, we examined cartilage degradation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b65a74b2fe861890953043093838cf6
https://dspace.library.uu.nl/handle/1874/363420
https://dspace.library.uu.nl/handle/1874/363420
Autor:
Gergana Galabova, José W.A. van der Hoorn, Marianne G. Pouwer, Hans M.G. Princen, Christine Landlinger, Elsbet J. Pieterman, J. Wouter Jukema, Guenther Staffler, Claudia Juno
Publikováno v:
European Heart Journal, 32, 38, 2499-2507
European Heart Journal, 38(32), 2499-U143
European Heart Journal, 38(32), 2499-U143
Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46ac81cf34d192dafc084e7052c98244
http://resolver.tudelft.nl/uuid:31d3da74-88bf-479b-a516-90503763d0fe
http://resolver.tudelft.nl/uuid:31d3da74-88bf-479b-a516-90503763d0fe
Autor:
N. Worms, Viktoria Gusarova, Hans M.G. Princen, N. Keijzer, Marianne G. Pouwer, J. Gromada, Joop Jukema, E.J. Pieterman
Publikováno v:
Atherosclerosis. 287:e12
Autor:
J.W. Jukema, G. Camejo, J.W.A. van der Hoorn, Louis M. Havekes, E. Lundholm, P.C.N. Rensen, Hans M.G. Princen
Publikováno v:
British Journal of Pharmacology. 156:1067-1075
Background and purpose: We have evaluated the effects of a peroxisome proliferator-activated receptor (PPAR)α/γ agonist on the progression of pre-existing atherosclerotic lesions in APOE*3Leiden.cholesteryl ester transfer protein (E3L.CETP) transge
Autor:
R. Kleemann, Wolfgang Koenig, J de Vries-van der Weij, Lars Verschuren, T. Kooistra, Hans M.G. Princen, Karin Toet
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology, 10, 26, 2322-2330
Objective— To demonstrate, quantify, and mechanistically dissect antiatherosclerotic effects of fenofibrate besides lowering plasma cholesterol per se. Methods and Results— ApoE*3Leiden transgenic mice received either a high-cholesterol diet (HC)
Autor:
E.H. Offerman, Astrid Trion, Arnoud van der Laarse, Wouter Jukema, Moniek P.M. de Maat, Louis M. Havekes, Jef J. Emeis, Annemarie C.E. Maas, Hans M.G. Princen, Alexander J. Szalai
Publikováno v:
Journal of Cardiovascular Pharmacology, 47(1), 89-95. Lippincott Williams & Wilkins
We investigated the pleiotropic effects of a calcium antagonist (amlodipine) on early atherosclerosis development in the presence and absence of an HMG-CoA-reductase inhibitor (atorvastatin) in apolipoprotein E*3-Leiden/human C-reactive protein (E3L/
Autor:
Joyce Chi Yee Chan, Simon Jackson, Hans M.G. Princen, José W.A. van der Hoorn, Scott M. Wasserman, Elsbet J. Pieterman, Brandon Ason, Kathy Nguyen, Susan Shetterly, Mei Di, Margrit Schwarz, J. Wouter Jukema, Jie Tang, Edward Lee, Rob Scott, Wen-Chen Yeh
Publikováno v:
Journal of Lipid Research, 55(11), 2370-2379
Journal of Lipid Research, Vol 55, Iss 11, Pp 2370-2379 (2014)
Journal of Lipid Research, 11, 55, 2370-2379
Journal of Lipid Research, Vol 55, Iss 11, Pp 2370-2379 (2014)
Journal of Lipid Research, 11, 55, 2370-2379
LDL cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C clearance. The therapeutic potential for PCSK9 inhibitors is highlighted by the fact that PCSK9 l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a39084ecc72a660fcf4dd482ee87539a
https://hdl.handle.net/1887/103264
https://hdl.handle.net/1887/103264
Autor:
Gerwin J. Puppels, J. Wouter Jukema, Sweder W.E van de Poll, Louis M. Havekes, Hans M.G. Princen, Arnoud van der Laarse, Dianne J.M. Delsing
Publikováno v:
Journal of Molecular and Cellular Cardiology, 35(1), 109-118. Academic Press
Combined treatment of statins and calcium channel blockers has been suggested to be superior to statin therapy alone. We quantified the anti-atherosclerotic potential of amlodipine, atorvastatin and their combination on existing atherosclerotic plaqu